Refine by
Drug Integrity Articles & Analysis
35 news found
BC Platforms has embedded NVIDIA accelerated computing into BC Mosaic, its trusted research environment, enabling faster GPU-powered analytics and AI-led analyses across clinical, multi-omics, and real-world data to support precision medicine and accelerated drug development.NVIDIA integration in BC MosaicNVIDIA technology is now natively available within BC ...
Integrated drug discovery services combine biology, medicinal chemistry, pharmacology and other sciences with cutting-edge technology to create new therapeutic options. As an antiviral preclinical contract research organization, Creative Diagnostics has enhanced its ability to provide a full range of services from target identification and validation, lead ...
In an era where technological advancements are constantly reshaping the landscape of the pharmaceutical industry, Protheragen-ING has emerged as a frontrunner with its cutting-edge AI-synthesizer for small molecule drug synthesis. This revolutionary platform is transforming traditional drug formulation processes by employing a unique combination of machine ...
In today’s evolving pharmaceutical landscape, the search for new drug delivery systems (DDS) is of paramount importance to improving therapeutic outcomes. ...
In exciting news, Protheragen-ING officially become a member of the Drug, Chemical & Associated Technologies (DCAT) Association. This move marks a significant milestone for Protheragen-ING and highlights the company's commitment to collaboration, innovation, and growth within the global pharmaceutical community. ...
Customization for Personalized Medicine: Antibodies are tailored to individual patient profiles, enhancing the potential for personalized medicine and increasing treatment efficacy while minimizing side effects. 5. Integration with Protein Drug Design: CD ComputaBio's platform seamlessly integrates Antibody De Novo Design with Protein ...
Additionally, data from the PARIS Test is used to accelerate drug discovery by identifying optimal patient populations for specific drugs. About SEngine Precision Medicine SEngine Precision Medicine Inc. is revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D tumor models and engaging in drug discovery. ...
August 29, 2022, Baltimore, MD and Indianapolis, IN – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the launch of a partnership with Helix BioStructures, a pharmaceutical-biotech contract research organization that provides high-quality, integrated drug ...
“The power of SEngine’s PARIS® platform to improve patient outcomes by providing oncologists individual drug effectiveness rankings as well as the innovation of new drugs will continue to propel SEngine ...
CD BioSciences, a leading customer-focused biotechnology company based in New York, introduces new GPCR purification services to support and facilitate GPCR research and drug development. CD BioSciences has built an unparalleled GPCR purification platform to provide the most reliable service for researchers. ...
Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. ...
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. Under ...
ByIktos
Packaging is another factor that decides the stability and integrity of drugs. Except for the role as an excipient producer and supplier, the US-based CRO company CD Formulation today announces that it newly launches a wide range of pharmaceutical packaging services, providing support throughout the whole process of packaging design, from material selection to ...
Logica leverages Valo’s AI-powered Opal Computational Platform and Charles River’s leading preclinical expertise, providing clients with transformed drug discovery with a single integrated offering seamlessly translating targets to candidate nomination. ...
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure, whose mission is to accelerate the preclinical development of innovative drugs through structural insight, recently established a MagHelix™ CADD Platform, a comprehensive platform for new drug discovery that integrates a variety of computer ...
” About PARIS® Test The PARIS® Test is a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with drug sensitivity testing of patient-derived live cells combined with robotics and proprietary algorithms. ...
To accelerate preclinical development for biologic drug developers, Thermo Fisher recently introduced its enhanced Quick to Clinic solution, designed to help biopharma companies reach Phase I/First-In-Human trials and file for Investigational New Drug (IND) review in as little as 13 months from transfection. Global Drug Product and Steriles ...
The Test pre-screens a broad panel of cancer drugs on live patient-derived tumor cells with a battery of oncology drugs selected from a menu of targeted and less-toxic medications. ...
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product ...
As part of Lonza's continued investment in China, a new drug product fill and finish manufacturing line will be installed at its Guangzhou (CN) site The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product ...